NEWS
Nearly 40 Institutions Participate in Aimei vaccines Investor Open Day Event
On December 27th, Aimei vaccines announced that the company held an investor open day event on December 22nd. Nearly 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited Aimei vaccines' bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production bases in Ningbo. They conducted on-site visits, discussions, and exchanges to gain a detailed understanding of the company's upcoming innovative vaccine products set to go public and the status of their production workshops, as well as the company's product pipeline layout and development plans.
Investors successively visited the two completed vaccine factories, including the serum-free iteration rabies vaccine workshop, new process human diploid cell rabies vaccine workshop, mRNA vaccine workshop, as well as the iteration pneumonia vaccine workshop, quadrivalent meningococcal conjugate vaccine workshop, Hib-DTP combined vaccine workshop, and modern quality control laboratory. Samples for the Phase III clinical trials of the soon-to-be-launched serum-free iteration rabies vaccine, PCV13, and PPSV23 were all produced in these workshops.
It was reported that Aimei vaccines' latest developed serum-free iteration rabies vaccine is an upgraded product. Compared with "serum-containing rabies vaccines" currently available in the market, this vaccine represents a technological breakthrough by eliminating any animal serum, enhancing safety, and reducing adverse reactions. This product is expected to apply for market approval next year.
Regarding the pneumonia vaccine series, the company has developed a series of polysaccharide conjugate vaccine products using its platform advantages. It is anticipated that the PCV13 and PPSV23 will apply for registration and listing in 2024. Additionally, Aimei vaccines has pioneered the development of iterated upgraded products, the 20-valent pneumococcal conjugate vaccine, and the 24-valent pneumococcal conjugate vaccine. Currently, the 20-valent pneumococcal conjugate vaccine is in the early communication stage with the Center for Drug Evaluation (CDE).
Regarding the market's attention to the launch process of the PCV13, Aimei vaccines stated that the product's production line has already completed production verification, and samples for the Phase III clinical trial were all produced on this production line. This will significantly expedite the entire product launch process by bypassing subsequent bridging trial stages.
In addition, Aimei vaccines also mentioned that the company is paying close attention to the application of vaccines in non-communicable disease areas and has actively embarked on research and exploration related to tumor vaccines such as melanoma, lung cancer, Alzheimer's disease vaccines, and diabetes vaccines.
Talking about its internationalization strategy, Aimei vaccines stated that the company's future focus on the international market will center on Southeast Asia, Africa, South America, the Middle East, and may not exclude entering the European and American markets.
Investors successively visited the two completed vaccine factories, including the serum-free iteration rabies vaccine workshop, new process human diploid cell rabies vaccine workshop, mRNA vaccine workshop, as well as the iteration pneumonia vaccine workshop, quadrivalent meningococcal conjugate vaccine workshop, Hib-DTP combined vaccine workshop, and modern quality control laboratory. Samples for the Phase III clinical trials of the soon-to-be-launched serum-free iteration rabies vaccine, PCV13, and PPSV23 were all produced in these workshops.
It was reported that Aimei vaccines' latest developed serum-free iteration rabies vaccine is an upgraded product. Compared with "serum-containing rabies vaccines" currently available in the market, this vaccine represents a technological breakthrough by eliminating any animal serum, enhancing safety, and reducing adverse reactions. This product is expected to apply for market approval next year.
Regarding the pneumonia vaccine series, the company has developed a series of polysaccharide conjugate vaccine products using its platform advantages. It is anticipated that the PCV13 and PPSV23 will apply for registration and listing in 2024. Additionally, Aimei vaccines has pioneered the development of iterated upgraded products, the 20-valent pneumococcal conjugate vaccine, and the 24-valent pneumococcal conjugate vaccine. Currently, the 20-valent pneumococcal conjugate vaccine is in the early communication stage with the Center for Drug Evaluation (CDE).
Regarding the market's attention to the launch process of the PCV13, Aimei vaccines stated that the product's production line has already completed production verification, and samples for the Phase III clinical trial were all produced on this production line. This will significantly expedite the entire product launch process by bypassing subsequent bridging trial stages.
In addition, Aimei vaccines also mentioned that the company is paying close attention to the application of vaccines in non-communicable disease areas and has actively embarked on research and exploration related to tumor vaccines such as melanoma, lung cancer, Alzheimer's disease vaccines, and diabetes vaccines.
Talking about its internationalization strategy, Aimei vaccines stated that the company's future focus on the international market will center on Southeast Asia, Africa, South America, the Middle East, and may not exclude entering the European and American markets.
